Cytokinetics: On The Cusp Of Commercialization
Cytokinetics: On The Cusp Of Commercialization Source link Bret Jensen
Cytokinetics: On The Cusp Of Commercialization Read More »
Apple: Investors Betting That ‘Things Are Different This Time’ (NASDAQ:AAPL)
This article was written by Follow Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns. Bret leads the investing
Apple: Investors Betting That ‘Things Are Different This Time’ (NASDAQ:AAPL) Read More »
SPY: 5 Charts Show How Overvalued The Market Has Become (NYSEARCA:SPY)
This article was written by Follow Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns. Bret leads the investing
SPY: 5 Charts Show How Overvalued The Market Has Become (NYSEARCA:SPY) Read More »
Zynex, Inc.: 2025 Looks Like A Brighter Year
Zynex, Inc.: 2025 Looks Like A Brighter Year Source link Bret Jensen
Zynex, Inc.: 2025 Looks Like A Brighter Year Read More »
3 Predictions For The Fourth Quarter
3 Predictions For The Fourth Quarter Source link Bret Jensen
3 Predictions For The Fourth Quarter Read More »
Certara: Still Awaiting Consistent Growth (NASDAQ:CERT)
Olga Seifutdinova/iStock via Getty Images It has been nearly 11 months since our last look at Certara, Inc. (NASDAQ:CERT). This small-cap concern has somewhat of a unique niche in drug development. We concluded our last article on this name saying
Certara: Still Awaiting Consistent Growth (NASDAQ:CERT) Read More »
5 Market Predictions For September
Kemter Both optimists and pessimists contribute to society. The optimist invents the airplane, the pessimist the parachute.”- George Bernard Shaw. It is difficult to believe that we are already almost all the way through August and mostly through the Dog
5 Market Predictions For September Read More »